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Abstract
Background: The majority of older people (> 65 years) in hospital have frailty and are at increased risk of
readmission or death following discharge home. In the UK, following acute hospitalisation, around one third of
older people with frailty are referred on for rehabilitation, termed ‘intermediate care’ services. Although this
rehabilitation can reduce early readmission to hospital (< 30 days), recipients often do not feel ready to leave the
service on discharge, suggesting possible incomplete recovery. Limited evidence suggests extended rehabilitation is
of benefit in several conditions and there is preliminary evidence that progressive physical exercise can improve
mobility and function for older people with frailty, and slow progression to disability. Our aim is to evaluate the
effectiveness of the Home-based Older People’s Exercise (HOPE) programme as extended rehabilitation for older
people with frailty discharged home from hospital or intermediate care services after acute illness or injury.
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Methods: A multi-centre individually randomised controlled trial, to evaluate the clinical and cost-effectiveness of
the HOPE programme. This individualised, graded and progressive 24-week exercise programme is delivered by
NHS physiotherapy teams to people aged 65 and older with frailty, identified using the Clinical Frailty Scale,
following discharge from acute hospitalisation and linked intermediate care rehabilitation pathways. The primary
outcome is physical health-related quality of life, measured using the physical component summary score of the
modified Short Form 36- item health questionnaire (SF36) at 12 months. Secondary outcomes include self-reported
physical and mental health, functional independence, death, hospitalisations, care home admissions. Plans include
health economic analyses and an embedded process evaluation.
Discussion: This trial seeks to determine if extended rehabilitation, via the HOPE programme, can improve physical
health-related quality of life for older people with frailty following acute hospitalisation. Results will improve
awareness of the rehabilitation needs of older people with frailty, and provide evidence on the clinical and cost-
effectiveness of the targeted exercise intervention. There is potential for considerable benefit for health and social
care services through widespread implementation of trial findings if clinical and cost-effectiveness is demonstrated.
Trial registration: ISRCTN 13927531. Registered on April 19, 2017.
Keywords: Older people, frailty, Ageing, Randomised controlled trial, Exercise, Physiotherapy, Rehabilitation, Quality
of life, Protocol, Process evaluation, Partially nested, Behaviour change, Complex intervention
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The Funder has had no role in trial
design, beyond setting the research
question the trial addresses. As such
the trial is designed specifically to
address certain aspects of a brief. In
designing the trial, the most significant
aspect was around the timely
implementation of ‘extended
rehabilitation’, after the acute/subacute
rehabilitation had finished and the
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Administrative information (Continued)
individual had been discharged home
from the acute or intermediate care
setting. Data collection, management,
analysis and interpretation will remain
independent of the Funder.
The Sponsor maintains oversight of trial
processes, but is not involved in trial
design or delivery processes. The
Sponsor will not participate in data
analysis or trial reporting processes.
Introduction
Background and rationale {6a}
Frailty is an especially problematic expression of
population ageing, with profound implications for
planning and delivery of health and social care services.
Frailty is characterised by reduced biological reserves
and increased vulnerability to adverse outcomes
including falls, disability, hospitalisation and care home
admission [1]. It develops through age-related decline in
several physiological systems, which collectively results
in a vulnerability to sudden health status changes trig-
gered by relatively minor stressor events. A majority of
older people (> 65 years) in UK hospitals have frailty and
are at increased risk of readmission or death following
discharge home [2, 3].
Sarcopenia (loss of muscle mass and strength) is a
core component of frailty [4, 5] and periods of
immobility in older age, such as those experienced
during an acute illness or injury, can accelerate loss of
skeletal muscle function [6]. Furthermore, the
inflammatory response commonly associated with acute
illness or injury can lead to catabolism of muscle protein
for generation of energy and immune proteins, further
accelerating loss of muscle mass and strength [1]. This is
especially problematic in frailty because accelerated loss
of skeletal muscle function can compromise the
capability to perform activities of daily living
independently (e.g. walking, dressing, toileting),
jeopardising successful functioning in the home
environment. This may then increase the need for home
care or admission to long-term care residence.
In the UK, following hospital admission with acute
illness or injury, approximately one third of older people
with frailty are provided with a period of rehabilitation
[7]. This National Health Service (NHS) rehabilitation is
often provided via ‘intermediate care’ (IC), which is a
range of community rehabilitation services
predominantly for older people with frailty to promote
recovery of independence and reduce premature need
for long-term care. IC is typically organised in two gen-
eral forms: bed-based rehabilitation, or home-based re-
habilitation [8], provided across a range of settings (e.g.
community hospital and hospital at home/community
therapy services). National guidelines for both bed-based
and home-based IC recommend only a brief contact (2
to 6 weeks) with services [9]. Findings from the 2014 UK
National Audit of Intermediate Care [9] identified that
many recipients of IC did not feel ready to leave the ser-
vice, indicating the possibility of incomplete recovery.
Although reduced early readmission to hospital (< 30
days) has been reported in five studies of IC [10], no dif-
ference in re-admissions between 60 days and 6 months
has been identified, indicating that the early benefits of
IC may not be sustained [11]. Indeed, the benefits of re-
habilitation in IC are shown to attenuate over time [12].
A key challenge is how to successfully reduce the loss of
independence that often affects older people with frailty
following hospital discharge. An intervention augment-
ing usual NHS rehabilitation, provided post-discharge
for older people admitted to hospital, is required to im-
prove longer-term outcomes. A programme of progres-
sive physical exercise with integrated behaviour change
techniques is a candidate intervention [13].
Exercise has positive physiological effects on skeletal
muscle, brain and endocrine systems [1]. Additionally,
observational studies have identified a consistent inverse
dose-response relationship between physical activity and
inflammation [14], which may be especially relevant fol-
lowing acute illness or injury. Randomised controlled
trial evidence indicates that exercise can down-regulate
inflammation in older people and that the benefit is
most pronounced in older people at greatest risk of dis-
ability and loss of independence [15]. Systematic reviews
of exercise interventions for older people with frailty
have reported evidence for improvements in mobility
and activities of daily living, but few studies used well-
validated frailty tools or measured effects on quality of
life and no studies reported on cost-effectiveness [13,
16–18]. Exercise programmes based on progressive
strength training were important for functional improve-
ment. This evidence for positive physiological, mobility
and functional benefits of exercise in frailty supports our
proposal for a home-based exercise intervention to ex-
tend the rehabilitation period for older people with
frailty following acute illness or injury.
Successful exercise programmes often incorporate
strategies to promote behaviour change. Behaviour
change strategies demonstrated to have a positive effect
on health behaviour adherence include goal setting, self-
monitoring, demonstration of behaviour, provision of
feedback, use of materials such as exercise logs and
manuals, enablement through social support, and ex-
tended periods of contact/support from a health care
provider [19–22]. It is difficult to draw causal links be-
tween single behaviour change strategies and effective
health behaviour interventions due to the nuanced and
multifaceted nature of many health interventions and
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health care provider interactions. However, a successful
exercise programme supported by physiotherapists will
likely need to include many of these behaviour change
strategies as elements of the programme and its delivery.
We have developed and tested in a pilot randomised
controlled trial (RCT), a home-based exercise interven-
tion for older people with frailty (Home-based Older
People’s Exercise (HOPE) programme) [23] aimed at im-
proving strength, endurance and balance. The HOPE
programme development has been previously described
[23], utilising a staged approach to the synthesis of evi-
dence and a co-design approach and refinement process.
The intervention is presented to participants in an exer-
cise manual and delivered by community-based physio-
therapy teams. The manualised nature of the
intervention and use of face-to-face and telephone sup-
port is consistent with evidence-based strategies to pro-
mote physical activity behaviour change, and
intervention adherence [19, 20]. The HOPE programme
has been tested in an earlier pilot trial involving 84
community-dwelling older people, with evidence for
feasibility, acceptability, and potential for a positive, clin-
ically important intervention effect on mobility. In-
formed by previously effective behaviour change
programmes, the HOPE programme has been extended
by a further 12 weeks of telephone-based support for
intervention sustainability for the HERO trial [20].
Here we report the protocol for the HERO trial, a
multi-centre individually randomised controlled trial to
evaluate the clinical and cost-effectiveness of the HOPE
programme for older people with frailty discharged
home from hospital or IC services following admission
with acute illness or injury.
Objectives {7}
The overall aim is to establish whether the HOPE
programme plus usual care is a clinically and cost-
effective extended rehabilitation programme for older
people with frailty discharged home from hospital or
from IC services after acute illness or injury, when com-
pared with usual care alone.
The primary objective is to evaluate whether the
HOPE programme improves physical health-related
quality of life, measured using the Physical Component
Summary (PCS) of the Modified Short Form 36-item
health questionnaire (SF36) 12 months after
randomisation.
Secondary objectives evaluate whether the HOPE
programme:
1. Improves physical health at 6 months post-
randomisation, as measured by the Physical Com-
ponent Summary (PCS) of the SF36.
2. Improves mental health at 6 and 12 months post-
randomisation, as measured by the Mental Compo-
nent Summary (MCS) of the SF36.
3. Improves functional independence at 6- and 12-
month post-randomisation, as measured by the
Nottingham Extended Activities of Daily Living
(NEADL) and Barthel index.
4. Reduces hospital readmission rates, care home
admission rates, hospitalisation due to falls,
mortality and overall health and social care
resource use at 6 and 12 months post
randomisation.
5. Is cost-effective, as measured by differences in cost
of service use between groups and the incremental
cost-effectiveness ratios (ICERs) using quality-
adjusted life years (QALYs) derived from the Euro-
Qol 5 dimension health questionnaire, 5 level (EQ-
5D-5L) at 6 and 2 months.
We will also undertake an embedded process evaluation
to understand how the intervention is experienced and
understood by providers and recipients (participants and
their carers), and to explore organisational implications of
embedding and sustaining the intervention in preparation
for any wider NHS roll-out.
Internal pilot objectives
1. To assess whether the provision and acceptability of
the intervention meet the pre-defined progression
criteria thresholds, for the proportion of participants
receiving their first home visit within 3 weeks and re-
tention of intervention participants respectively.
2. To assess whether trial recruitment and 6-month
follow-up rates meet the pre-defined progression
criteria thresholds.
Trial design {8}
A multi-centre, parallel group, individually randomised-
controlled trial with internal pilot with clear progression
criteria and an embedded process evaluation. The inter-
vention arm has a hierarchical structure, as the interven-
tion will be delivered by therapists such that groups of
participants (level 1) will receive the intervention from
(are nested within) the same therapist (level 2), introdu-
cing clustering in the intervention arm only. No clustering
occurs in the control arm. Hence this trial is an example
of a two-level, partially nested hierarchical design.
Methods: participants, interventions and
outcomes
Study setting {9}
The study aims to recruit older people with frailty on
discharge from general/elderly care, trauma and
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orthopaedics wards or IC services (bed-based and home-
based) after an acute admission to hospital in fifteen
NHS hospital trusts within two geographical areas
(Yorkshire and South West England). Discharge will be
defined as returning home, and the cessation of rehabili-
tation following the acute admission. Study sites are
listed in Acknowledgements.
Site identification and eligibility {10}
Clinical and research leads for older people and therapy
services at English NHS Trust sites in Yorkshire &
Humber and the South West will be approached by the
HERO trial team and assessed for eligibility. A feasibility
questionnaire will determine if sites have services
appropriate to support recruitment, delivery of the
intervention, and support for trial-related research activ-
ity (e.g. data collection). Eligible sites include those with
elderly medicine/trauma and orthopaedics services pro-
vided at the acute hospital site, availability of bed-based
and home-based IC services that routinely receive the
trial population transferred from the acute hospital site,
agreement by therapy services manager that site recruit-
ment targets are feasible and acceptable for the service
to support intervention delivery. Sites already providing
routine extended rehabilitation service (> 6 weeks) for
older people with frailty following discharge home from
hospital or IC will be excluded.
Participant identification and eligibility
Participant recruitment will vary by site dependent upon
service infrastructure and usual NHS rehabilitation
patient pathways. These will be established during site
set-up and strategies will be put in place to maximise
identification and recruitment of potential patients. Pa-
tients will be screened on admission to the relevant
ward/service by local research staff. Those meeting the
following eligibility criteria will be identified through dis-
cussions with ward staff:
 Age ≥65 years.
 Admitted to general medicine/elderly medicine or
trauma and orthopaedics care following acute illness
or injury then discharged home from hospital or
from IC.
 Have mild, moderate or severe frailty, defined as a
score of five to seven on the nine-item Clinical
Frailty Scale (CFS).
 Ability to complete the Timed Up and Go Test
(TUGT) without additional external support.
 Ability to give informed consent to participate in the
study.
The following patients will be excluded:
 Permanent care home residents.
 Those with significant cognitive impairment at
baseline (defined as Montreal Cognitive Assessment
(MoCA) test < 20).
 Recent (< 3 months pre-randomisation) myocardial
infarction, or unstable angina.
 Very severe frailty (defined as score of eight on
CFS).
 Terminally ill (defined as score of nine on CFS).
 Receiving palliative care.
 Referral at discharge for condition-specific rehabili-
tation (e.g. pulmonary rehabilitation, stroke rehabili-
tation, falls prevention programme).
 Another household member in the study.
 Currently participating in the HERO trial or another
contraindicated study.
Documented reasons for ineligibility or declining
participation will be closely monitored by the Research
team as part of a regular review of recruitment progress,
to allow for generalisation of study results in accordance
with CONSORT reporting guidelines, and to highlight
any issues in the identification or recruitment of patients
during the internal pilot.
Who will take informed consent? {26a}
Local research staff will monitor potential participants
throughout their admission and seek informed consent
approximately 48 h prior to discharge home from
hospital or from IC. Eligible participants will be
approached and the study will be introduced to them
verbally. During this approach, the researchers will also
carry out an assessment of capacity to provide informed
consent to participate. Interested participants will be
given verbal and written information about the trial,
given appropriate time to consider involvement and
discuss participation with family/friends. Written
informed consent will be sought; this will be timed with
appropriate proximity to planned discharge. If the
potential participant has capacity and chooses to
consent, final eligibility assessments will be undertaken
(CFS, MoCA, TUGT) and, if appropriate, the baseline
assessments will be completed ahead of randomising the
participant to their treatment allocation.
Eligibility assessments
 Timed Up and Go Test (TUGT) [24]: measures time
(seconds) to stand from a chair, walk 3 metres, turn,
and return and sit down on the chair. Developed as
a basic mobility test for older people [24], the
original TUGT validation study identified that those
who complete the test in ≥30 s are likely to require
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assistance with walking, climbing the stairs and
leaving the house.
 Clinical Frailty Scale (CFS) [25, 26]: a well-
established ordinal (nine point) measure of frailty
that has been validated for use in the hospital set-
ting, with higher scores indicating more severe
frailty [25, 26]. Individual categories range from very
fit (category 1), to terminal illness (category 9). The
CFS is a simple tool that clinical and research staff
can routinely use to categorise frailty based on an
older person’s pre-admission health. This is in con-
trast with most performance-based frailty measures
(e.g. gait speed, grip strength), which can conflate ill-
ness severity or sudden changes in mobility with
frailty, so are unsuitable in the context of acute ill-
ness or injury.
 Montreal Cognitive Assessment (MoCA) [27]: a
rapid (≈10 min) screening instrument for mild
cognitive dysfunction [27] assessing a range of
cognitive domains: a score of 26 or above (from
possible 30) is considered normal, scores < 20
indicate the presence of significant cognitive
impairment [28].
Changes in capacity
If a member of the research team has concerns
regarding capacity to provide ongoing consent to
participate, a home visit will be scheduled to establish
capacity, willingness to continue participation supported
by appropriate consent, and support ongoing data
collection. This will include seeking advice from a
Personal Consultee regarding continued participation in
the study. If changes in capacity are noted during
intervention delivery the therapist will determine the
participant’s willingness and ability to continue with the
intervention, in accordance with routine clinical
judgements. If the participant is no longer willing to
continue with the intervention, this will be documented
as a withdrawal from treatment, with involvement in
additional activities and data collection to be reviewed
by the researcher at follow-up.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
If the consenting participant has a carer, consent for
carer participation in process evaluation activity will be
sought. A carer is defined as anyone who cares, unpaid,
for a friend or family members who due to illness,
disability or a mental health problem cannot cope
without their support. Carers who are anticipated to
provide support following the participant’s discharge
from hospital and are available to support HOPE
programme sessions if the participant is randomly
allocated to the intervention will be eligible. The local
researchers will approach an identified carer once their
linked trial participant’s consent has been gained and
eligibility has been confirmed.
Participant consent for 3rd party access to anonymised
trial data, for purposes of further medical research, is
included in the original consent.
Interventions
Explanation for the choice of comparators {6b}
Usual care is defined as ‘the wide range of care that is
provided in a community whether it is adequate or not,
without a normative judgment ’[29].
To increase external validity and relevance of study
findings to clinical practice, the study protocol does not
restrict access to usual care, in line with our pragmatic
study design [30] and the possibility for heterogeneity of
usual care treatments available for older people with
frailty. For example, usual care at a personal level will
depend on individual frailty, level of independence and
social predicaments. It is likely to include GP care,
district nurse input, and home care packages, but usual
care may also include the use of voluntary sector
services, day centres, and respite care. Use of and
referral to services (including other rehabilitation) will
be recorded at baseline and follow-up assessments in
both intervention and control groups.
Intervention description {11a}
A Template for Intervention Description and
Replication (TIDieR) checklist [31] is presented in Table
1. 0 in Appendix 1.
Criteria for discontinuing or modifying allocated
interventions {11b}
The intervention therapist will employ flexibility to
enable participants to progress or regress, within the
programme in line with their health and abilities at a
given time, guided by the therapist. If at any stage the
participant expresses a wish to pause the HOPE
programme, for example due to transient ill health, then
that will be accommodated.
Strategies to improve adherence to interventions {11c}
The therapist will use behaviour change strategies
appropriate to each participant to improve adherence to
the intervention. These include, but are not limited to,
individual goal setting, grading of programme, promote
self-monitoring (exercise diary). Therapists will complete
a therapy record for each participant documenting im-
plementation of the intervention, any deviations, and the
reasons for these deviations.
Prescott et al. Trials          (2021) 22:783 Page 6 of 17
Relevant concomitant care permitted or prohibited
during the trial {11d}
The study protocol does not restrict access/referral to
usual care services for any participants. Additional
interventions during the study period will be
documented as part of the usual care review. Should the
intervention therapist become aware of other new
referrals to services, the nature of that referral will be
established. The HOPE programme may be discontinued
or paused if there is a contraindication to the participant
receiving the HOPE programme and other services
concurrently.
Provisions for post-trial care {30}
All participants, when in contact with researchers for
purposes of data collection, or therapists for purposes of
intervention delivery, may at some stage highlight an
unmet care need. The researcher or therapist will then
signpost the participant appropriately. Additional
therapy outside the HOPE programme will not be
provided by the intervention therapists, nor is any
specific aftercare planned as part of the trial.
Outcomes {12}
Outcome data will be collected using self-report postal
questionnaires at 6 and 12 months to reduce the risk of
detection bias, by telephone assessment if physical dis-
ability prevents written communication, or by face-to-
face assessment for participants with early signs of cog-
nitive impairment who live alone, by a researcher with
experience of working and communicating with an older
population. Telephone and face-to-face follow-up assess-
ments will be performed blinded to treatment allocation,
where possible, for study participants requiring these
methods.
Primary outcome
The effectiveness of the HOPE programme will be
determined by the SF36 physical component summary
(PCS) score measured at 12 months post randomisation.
The eight individual scales that comprise the SF36
incorporate the aspects of health and well-being that are
relevant for quality of life in older age [32].
Secondary outcomes
Secondary outcomes measured at baseline, 6 and 12
months post randomisation (unless stated otherwise),
are listed below:
 PCS score of SF36 measured at 6 months.
 Mental component summary (MCS) score of SF36:
alongside mental health, this incorporates elements
of vitality and social functioning. It therefore has
face validity for capturing additional potential
benefits of rehabilitation.
 Barthel Index of activities of daily living [33] assesses
functional status on a 20 point scale by recording
ability to complete ten basic activities of daily living,
including bathing, dressing, toileting, mobility and
stairs.
 Nottingham Extended Activities of Daily Living
(NEADL) [34] measures help needed with
instrumental activities of daily living, including
walking around outside, doing the housework, using
the telephone.
 EuroQol5-Dimension Health Questionnaire (5
levels) (EQ-5D-5L) [35]: measures health-related
quality of life, comprising five dimensions: mobility,
self-care, usual activities, pain/discomfort and anx-
iety/depression. Scores are combined and converted
into a summary health utility index (0 for dead, 1 for
perfect health and negative values for states worse
than death).
 Hospital readmission rates, mortality and
hospitalisation due to falls, collected using routine
Hospital Episode Statistics (HES) and linked Office
for National Statistics (ONS) mortality data.
 Care home admission status, recorded by local
research staff, who review address details ahead of
postal follow-up, to identify those participants ad-
mitted to a care home.
 Healthcare Resource Use. In addition to routine
HES data, we will use an adapted version of the
Health Resource Use data collection form developed
for the NIHR Prevention of Falls Injury Trial (PreFit;
https://www.journalslibrary.nihr.ac.uk/projects/
081441/#/). The form will include health, informal
care, social care and voluntary sector resource.
 Falls questionnaire: participants will record number
of falls in the prior 6 months, and any broken bones
that resulted.
 Twelve-month usual care review: data collected by
site research teams from electronic databases at sites
regarding secondary and, if available, primary care
service use for participants in the 12 months since
randomisation.
Participant timeline {13}
The study timeline for participants is presented in Fig. 1,
outlining the schedule of enrolment and intervention
and Fig. 2, outlining assessment activities.
Sample size {14}
A sample of 742 participants (325 control, 417
intervention) will provide 90% power to detect a
minimum clinically important difference of 3 points in
the PCS, at the 2-sided 5% significance level. The
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calculations assume a mean PCS score of 30 (SD 9,47)
[36] and account for 35% loss to follow-up, clustering in
the intervention arm only, average cluster size 7 partici-
pants per therapist, an interclass correlation coefficient
of 0.03 [37, 38], and a coefficient of variation in cluster
size of 0.7 to account for a varying number of partici-
pants per therapist.
Recruitment {15}
Following admission to hospital with acute illness or
injury it is anticipated that around one third of frail
older people will be discharged directly home from
hospital, one third will transfer to IC for a short period
of rehabilitation, and one third will be admitted from or
discharged to a care home, so will be ineligible, or will
have died following admission. On the basis of a 30%
recruitment rate, estimates of hospital frailty prevalence,
national audit of intermediate care data and NHS
secondary care data, and informed by pilot work in
which 84 participants were recruited over a 16-month
period in a single-site (approximately five per month)
whilst ensuring feasibility of intervention delivery by
NHS therapy staff as part of routine care [39], we antici-
pate that recruitment estimates of 4–5 participants at
each site each month are achievable, realistic, and feas-
ible for intervention delivery across participating sites
considering therapy capacity.
Assignment of interventions: allocation
Sequence generation {16a}
Eligible and consenting participants will be individually
randomised with a 1.28:1 allocation ratio (HOPE + usual
care: usual care) following baseline data collection and
within 7 days post discharge. The higher allocation ratio
of the intervention arm accounts for a greater level of
correlation anticipated in the outcomes for those
receiving the HOPE programme, as a result of
participants treated by the same community therapy
staff.
The method of allocation will use a computer-
generated minimisation programme, incorporating a
random element, minimised by: site, discharge setting
(hospital, bed-based IC, home-based IC), intended level
of HOPE programme (level one, two or three) based
upon TUGT, and reason for admission (acute illness or
injury).
Concealment mechanism {16b}
Randomisation will be performed by an automated 24-h
randomisation service, operated by the CTRU via web
address and telephone, and accessible to trained re-
searchers with an authorisation code and PIN.
Implementation {16c}
Once a participant has consented, the researcher will
access a 24-h randomisation service. Following success-
ful randomisation, the researcher and site principal in-
vestigator will receive an automated email confirmation
from the randomisation service that randomisation was
successful, omitting details regarding allocation. Partici-
pants will be contacted via letter to confirm their trial al-
location, and outline trial procedures that will follow.
Following randomisation, therapy service managers
will be notified of participant recruitment via automated
email outlining details of participants randomised to the
intervention along with discharge date to enable referral
Fig. 1 Schedule of enrolment and interventions
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to a community therapist and intervention initiation. A
list of control participants will be maintained to manage
the risk of contamination from therapists delivering the
HOPE programme also delivering community services to
those in usual care.
Assignment of interventions: blinding
Who will be blinded {17a}
Owing to the nature of the intervention, it will not be
possible to blind participants or those involved in the
delivery of the intervention. The process evaluation will
assess the possibility of changed participant/clinical
behaviour as a result of this knowledge, and any
unanticipated effects.
General practices will be notified of participants’
enrolment on to the study; however, they will not be
informed of their allocation status to prevent clinical
behaviour change. Other health and social care teams
will not be informed about study participation or
allocation status.
Those responsible for data collection will be blind to
allocation. In the event a researcher becomes unblinded,
this will be reported to the CTRU and, where feasible,
subsequent follow-up assessments will be completed by
an alternative researcher. Data analysts will not be
blinded but a detailed statistical analysis plan will be
drafted in accordance with CTRU standard operating
procedures and will be finalised and agreed by the
Fig. 2 Schedule of assessments
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appropriate members of the research team and inde-
pendent trial steering committee before any analyses are
undertaken.
Procedure for unblinding if needed {17b}
Trial participation will be recorded in participants’
hospital notes and with their GP. This will not reveal
allocation, but will detail where further information can
be gained if required. We do not envisage a situation
where allocation needs to be revealed outside of regular
office hours.
Data collection and management
Plans for assessment and collection of outcomes {18a}
The schedule for participant assessments is summarised
in Fig. 1: Schedule of enrolment, interventions, and
assessments.
Baseline data for all eligible and consenting
participants will be collected by the local researcher in
the 48 h prior to discharge. These data will be collected
directly from the participant, supplemented where
appropriate by the team providing care/rehabilitation,
and associated records. If discharge is delayed,
assessments will be reviewed and repeated where
applicable. In addition to outcomes data, the following
data will also be collected at baseline:
 Charlson Comorbidity Index [40]: a validated
measure used to combine the risk from age, and the
risk from comorbid disease into a single variable
estimating the risk of death. Higher scores indicate
greater comorbidity burden.
 Demographic/descriptive data includes: initials, date
of birth, gender, NHS number, ethnicity, living
arrangements, employment status, details of hospital
admission (reason, date of admission and discharge,
discharge from setting), any requirement for
researcher supported follow-up at 6 and 12 months.
 Carer contact details and demographics: address,
telephone number, age, gender, relationship to
participant, care responsibilities.
At 6- and 12-month follow-up, if postal questionnaires
are not received back at the CTRU after 3 weeks, a re-
minder letter and second questionnaire will be posted. If
data is not received after two more weeks, local re-
searchers will be asked to establish contact with the par-
ticipant to offer support, collecting the data over the
telephone or via a face-to-face home visit.
Safety data collection and status check for each
participant will be requested from sites by the CTRU at
5 and 11 months post randomisation for each
participant. Safety data include hospitalisations due to
fall and/or fracture. Status check includes mortality and
review of contact details which will inform postal
questionnaire request at 6 and 12 months.
Site research teams will collect usual care data on
secondary and primary care services used by participants
when prompted by the CTRU, after 12-month follow-up
participant data collection is complete. This will avoid
unblinding, if researcher support is required for the par-
ticipant follow-up assessment.
An application will be made to NHS Digital for HES
and linked ONS mortality data, timed to coincide with
end of the participant follow-up, in a single data down-
load. There is scope for triangulation of data collected
from participants, sites and HES around health care re-
source use.
All researchers recruiting trial participants and/or
involved in data collection will receive initial and
ongoing training in data collection tools and trial
processes. After initial training, regular communication
will be maintained via newsletters, recruitment updates,
researcher update teleconferences, and targeted site
communications regarding altered trial process. We will
also maintain an up-to-date website with trial protocol,
contact details and other material. Data collection forms
are available on request at ctru-dataaccess@leeds.ac.uk.
Plans to promote participant retention and complete
follow-up {18b}
Initial letters, reminder letters and engagement cards
will be used to maximise data return at all-time points.
Participant engagement cards precede follow-up by 1
month. These attractive picture cards include a message
from the Chief Investigator thanking participants for
their participation in the trial. The message reminds par-
ticipants of the trial purpose: how their data contributes,
and of the imminent data collection time point. Partici-
pants will receive an unconditional monetary incentive
of a £5 gift voucher at each follow-up. A pen will also be
sent out with follow-up assessments at both 6 and 12
months for ease of completion and return. As required,
researchers will support follow-up. Participant’s family/
friends can also support the completion of the assess-
ment. Primary outcome data will be prioritised at the
start of the data collection process, and when appropri-
ate, data collection may be staged over additional days,
according to participants’ fatigue and at researchers’
discretion.
Participants will be free to withdraw consent and leave
the study at any time without giving reasons and
without affecting their care. If a participant withdraws
consent to participate, clarification will be sought on
whether withdrawal is from, for example, participation
in the intervention, questionnaire completion or access
to health and social care records. Previously collected
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pseudo-anonymised data will still be used in the
analyses.
Individual assessments will not be carried out where
the participant appears reluctant to participate (i.e. no
response to telephone contacts). However, in the
absence of a withdrawal request, outcome data that do
not involve participant contact (e.g. from medical or
healthcare records) will continue to be collected in these
cases.
Data management {19}
All case report forms sent or received by the CTRU will
be coded with the participant’s study number, initials,
date of birth and site code. Data will be held securely on
paper and entered on a secure electronic database at
CTRU. All relevant Standard Operating Procedures,
Guidelines and Work Instructions in relation to data
management, processing and analysis of data will be
followed. CTRU will provide sites with a file to safely
maintain essential study documentation and for the
retention of completed case report forms and
assessments for the study. Interviews for the process
evaluation will be audio recorded and professionally
transcribed, with any identifiable information removed.
Audio files will be securely transferred in encrypted
format and stored at the Academic Unit for Ageing and
Stroke Research (AUASR).
Confidentiality {27}
All information collected during the study will be kept
strictly confidential, and handled in accordance with the
consent provided, adhering to the Data Protection Act,
2018 [41]. All relevant procedures will be followed for
processes of transfer, storage, restricted access and
disposal of personal information. Upon study
completion, sites will archive all study data until
authorisation for confidential destruction is provided by
the study sponsor. The Trial Master File and documents
held by the CTRU will be archived at a secure facility at
the University of Leeds.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
A detailed Statistical Analysis Plan (SAP) outlined in this
section will be written and approved by the appropriate
members of the research team before any formal
analyses are undertaken. Following analysis of the
progression criteria from the internal pilot, no formal
interim analyses are planned. A single final analysis is
planned after study closure, when the full database has
been cleaned and locked. Statistical analyses will be
according to the ITT principle, and statistical
significance will be assessed at the two-sided 5%
significance level. The ITT population is defined as ana-
lysis according to the randomisation and regardless of
compliance with the protocol or withdrawal from the
trial.
Primary analysis
The primary outcome will be compared between arms
using a linear mixed-effects heteroscedastic model to ac-
count for clustering of outcomes in the intervention arm
due to therapist effects [42]. The model will be adjusted
for the stratified design factors, age, sex, baseline meas-
ure of the outcome, and participant previous engage-
ment or referral to community rehabilitation services.
Corresponding 95% confidence interval and p values will
be reported as well as the adjusted and unadjusted ICC
for the intervention arm. Model diagnostics will be used
to check that the underlying assumptions are not
violated.
Secondary outcomes
Secondary outcomes of SF36 MCS score, Barthel Index,
NEADL scores, EQ-5D-5L summary index, and A&E at-
tendance or hospital admissions due to falls will be ana-
lysed using the same methods as described for the
primary outcome and adjusted for the same stratification
and participant level covariates. The analysis of the SF36
MCS score will additionally adjust for the baseline SF36
PCS score.
The binary secondary outcomes of new care home
placement, hospital readmission, composite of new care
home placement or hospital readmission and mortality
will be compared between arms using logistic
generalised estimating equations or random intercept
models to account for heteroscedasticity [43], adjusted
for stratification factors and age.
Intervention implementation
Descriptive statistics will be used to summarise
quantitative data collected on intervention
implementation via therapy records and exercise diaries
for all intervention participants. This data will support
more detailed analysis of intervention fidelity evaluated
as part of the process evaluation.
Internal pilot
Descriptive statistics will be used to evaluate progression
criteria assessing the level of recruitment for each site,
follow-up rates, as well as provision and acceptability of
the intervention. This analysis will inform study continu-
ation beyond the internal pilot phase. The progression
criteria will be assessed based on a traffic light system of
green (go), amber (review) and red (stop), as follows:
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Provision of intervention (assessed at 6 months after
the start of internal pilot recruitment) Green: ≥80% of
intervention participants receiving their first home visit
within 3 weeks
Amber: < 80% but ≥65% of intervention participants
receiving their first home visit within 3 weeks
Red: < 65% of intervention participants receiving their
first home visit within 3 weeks
Acceptability of intervention (assessed at 9 months
after the start of internal pilot recruitment) Green:
≥80% retention of intervention participants
Amber: < 80% but ≥65% retention of intervention
participants
Red: < 65% retention of intervention participants
Recruitment (assessed at 6 months after the start of
internal pilot recruitment) Green: ≥4 patients/month/
site (measured in months four to six to allow time for
recruitment to stabilise)
Amber: < 4 but ≥2 patients/month/site
Red: <2patients/month/site
Six-month follow-up (assessed at 12 months after the
start of internal pilot recruitment) Green: ≥80%
completion of the SF-36 physical component summary
Amber: < 80% but ≥65% completion of the SF-36 phys-
ical component summary
Red: < 65% completion of the SF-36 physical compo-
nent summary
If any criteria are graded as amber, a rescue plan will
be developed outlining steps to be taken to improve
intervention provision, recruitment, retention and/or
follow-up (as appropriate), and will be approved by the
TSC before submission to the funder. If the progression
criteria are failed (red), then the internal pilot will not
progress to the definitive study. If the progression cri-
teria are met by the end of the internal pilot then the
study will continue and outcome data from participants
in the internal pilot will be included in the main study
analysis.
Interim analyses {21b}
No formal interim analyses are planned for outcomes.
The descriptive data pertaining to the internal pilot will
be compiled based on the first 6 months recruitment
and associated participant data.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
There are no sub-group analyses planned.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Missing outcomes, especially those due to death, may
not be missing at random, hence first we will explore
and summarise the missing data patterns and reasons
for missingness to guide the appropriate analytical
strategy. If this work confirms that it is reasonable to
assume data are missing at random (MAR), the primary
analysis will use multiple imputation to deal with
missing data. We will include a wide range of variables
in the imputation models, including all variables in the
substantive analysis, plus, as far as computationally
feasible, all variables predictive of the missing values
themselves (including potentially time of death) and all
variables influencing the process causing the missing
data, even if they are not of interest in the substantive
analysis. If the initial work does not confirm MAR, we
will explore the use of other more complex methods for
the primary analysis taking account of data missing not
at random (MNAR), such as pattern mixture modelling.
To assess the impact of death on our potential
treatment effect, we will then undertake a sensitivity
analysis by repeating the primary analysis modelling but
exclude those participants who have died. A per
protocol analysis or Complier Average Causal Effect
Model of the primary outcome will also be conducted
based on pre-defined criteria associated with interven-
tion adherence.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
The HERO trial web page (www.bradfordresearch.nhs.
uk/hero/) contains the latest version of the trial
protocol. Trial outputs will be published in open access
journals. Upon study completion, any party may apply to
the Chief Investigator and trial team for access to the
full protocol and anonymised participant-level data for
academic research purposes. An information governance
committee including senior trial methodologists will
govern data access.
Economic evaluation
We will carry out within-trial and long-term cost-
effectiveness analyses. Analyses will report differences in
cost of service use between groups and the ICERs using
quality-adjusted life-years (QALYs) derived from EQ-
5D-5 L[35].
The primary within-trial analysis will compare direct
costs and 12-month outcomes of participants rando-
mised to the HOPE programme (+ usual care) versus
control (usual care alone). The perspective adopted will
be that of the NHS and Public Social Services. Secondary
analyses will adopt a societal perspective taking account
of productivity costs and out-of-pocket expenditures
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incurred by participants. Data collected at baseline, 6
and 12 months will be utilised to estimate incremental
cost-effectiveness ratios comparing the intervention with
the control group. Mortality and quality of life (derived
from the EQ-5D-5L) over the study period will be used
to generate QALYs [44]. Sensitivity analyses will con-
sider key cost drivers and factors that might affect the
outcomes measured to explore uncertainty in the con-
clusions drawn [45]. Utility values derived from the SF36
(SF6D) will be included as a sensitivity analysis.
The long-term cost-effectiveness model will again
compare effectiveness of the HOPE programme (+ usual
care) versus control (usual care alone), from the perspec-
tive of the health and social care providers. The decision
analytic cost-effectiveness analysis model will use a life-
time horizon to capture the full impact of any mortality
differences on the long-term cost-effectiveness. The
model will be a Markov or semi-Markov state model.
Transition rates for the model will be estimated from
the clinical study data. Where this is not possible (e.g.
outcomes of hospital readmission/care home placement),
we will follow recommended best practice in identifying
and synthesising the best available evidence in the
literature.
The primary outcome measure will be the QALY.
Utility weights will be taken from the tariff
recommended by NICE at the time of analysis. Unit
costs will be taken from national databases including
NHS reference costs and the PSSRU costs of health and
social care. Probabilistic sensitivity analyses will be
undertaken using Monte Carlo simulation techniques.
The outputs reported from the analysis will be the same
as for the within-study analysis.
Process evaluation
In line with the Medical Research Council guidelines
[46] an embedded process evaluation will be undertaken.
This will use documentary analysis, non-participant ob-
servation and semi-structured interviews to explore and
understand the implementation of the intervention, and
how it is experienced and understood by providers and
recipients.
In addition to main trial participation, trial recruits
and their carers will be asked to optionally consent to
potential participation in the process evaluation. A
purposeful sample of consented individuals will be
approached across ten trial sites throughout the
intervention delivery phase of the trial. Purposive
sampling is planned for all types of data collection
associated with the process evaluation. The intention is
to sample participants with different levels of frailty,
level of intervention, gender and age. We will also
sample, through observations, intervention delivery at
different time points, including first and last visits by
therapists or therapy assistants. Trial intervention
therapists and therapy service managers will also be
approached to consent to their potential involvement in
process evaluation activities. Sampling for therapists will
seek to include different levels of qualification and years
of experience, different gender as well as different sites
and regions. Where possible we will sample therapists
who have completed intervention delivery to a minimum
of three participants.
Consented carers will be approached for process
evaluation involvement in line with the participant
purposeful sample. Usual care participants will be
sampled similarly and invited for interview. Purposive
sampling will also be undertaken as part of the
documentary analysis in order to ensure records are
reviewed from a range of different therapists and
participants.
Researchers undertaking the process evaluation will:
 Observe and monitor intervention therapist training,
and their engagement with training.
 Engage in informal discussion with therapy teams in
early and late stages of intervention delivery to
understand how organisational and professional
contexts impact on rehabilitation provision to the
participant group.
 Interview therapy service managers to establish what
constitutes usual care across trial sites.
 Observe home-based delivery of the HOPE
programme in a sample of participants across par-
ticipating sites and across participants with a range
of degrees of frailty. Observations will include the in-
teractions between therapists, participants and fam-
ily members/carers (where present), and note
contextual factors potentially influencing
programme delivery, receipt and enactment.
 Interview a purposive sample of intervention
delivery staff.
 Interview a purposive sample of intervention
participants (including those who did and did not
engage with the intervention). Carers will also be
invited to participate in the semi-structured inter-
views where it is apparent they have some involve-
ment in supporting participants with the
intervention, and/or usual care.
 Interview a purposive sample of trial participants
allocated to usual care arm of the trial. This will
establish whether they participated in other
programmes post discharge provided by the NHS,
social care, voluntary or private sector, which may have
included similar structured exercise provision, and
whether this was evident in particular regions or sites.
 Evaluate intervention adherence using data from
participant exercise diaries and therapy records.
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Normalisation Process Theory (NPT) will provide the
framework for process evaluation [47]. Quantitative and
qualitative data to evaluate intervention fidelity will be
analysed using descriptive statistics, and content
analysis. Field notes and interview data will be analysed
using a thematic approach [48].
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
Study oversight will be provided by the independent
Trial Steering Committee (TSC), who will meet every 6
months. This comprises of four professionals within a
research field involving our study population, with
expertise in our trial methodology (statistics, health
economics, process evaluation, rehabilitation trials and
elderly medicine). The TSC also include two lay
personnel who will bring knowledge and expertise from
the study population and service user perspective.
The trial management group (TMG) will include the
chief investigator and grant co-applicants, CTRU trial
management personnel, AUASR trial management and
process evaluation teams, and Academic Unit of Health
Economics personnel at both the University of Leeds
and the University of Exeter. The TMG will also include
two lay personnel who will bring knowledge and expert-
ise from the study population and their carers’ perspec-
tive. The TMG meetings will be scheduled on a
quarterly basis as a minimum, but monthly in the initial
phase of trial setup; responsibilities include the set-up
and promotion of the trial, on-going monitoring and
management of the trial and interpretation and dissem-
ination of results.
Composition of the data monitoring committee, its role
and reporting structure {21a}
For a study of this nature, a separate Data Monitoring
Committee is not required. Rather the TSC will adopt a
safety monitoring role, with a sub-committee to review
safety issues where necessary.
Safety data (deaths and hospitalisation resulting from
falls and/or fractures), collected at 5 and 11 months per
participant, will be reported by arm to each TMG and
TSC meeting and escalated as appropriate. An annual
safety report is produced for REC. As deaths are
expected within the study population they will not be
subject to expedited reporting to the REC, unless the
TSC advises otherwise.
Adverse event reporting and harms {22}
Adverse Events will be reported by sites if classified as
related or unexpected (related to the study intervention).
Trial sites will be trained in the timely reporting
procedures for Suspected and Unexpected Serious
Adverse Reactions/Events. Expected Adverse Events data
will be reported by trial sites at 5 and 11 months per
participant (including death, and hospitalisation rates
due to falls and/or fracture). Participants are asked
regarding falls and fracture incidence at 6- and 12-
month follow-up. We do not specifically ask participants
to describe other experienced harms, other than via op-
portunities to observe and discuss adherence related is-
sues via the process evaluation activity. Safety data as
described above will be reported by arm in the final trial
report.
Frequency and plans for auditing trial conduct {23}
Researchers will notify the CTRU if there is a breach of
protocol or Good Clinical Practice principles likely to
significantly affect participants’ safety, health and
wellbeing, or scientific value of the research.
The CTRU/Sponsor reserve the right to conduct
intermittent source data verification on a sample of
participants. Source data verification will involve direct
access to patient notes at the participating hospitals, and
other relevant investigation reports.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Protocol amendments will be processed in line with
HRA and REC guidelines and processes. Sites and
investigators will be notified and agreement/capacity to
implement sought.
Dissemination plans {31a}
The NIHR Yorkshire and Humber Applied Research
Collaboration (ARC) Research Implementation Advisory
Group (RIAG) will be approached to discuss the trial
results and potential dissemination of outputs.
Representatives of NHS England and Public Health
England will be on the RIAG, along with NHS and local
authority commissioners and providers, facilitating
widespread dissemination. We will also involve the
National ARC Healthy Ageing, Frailty and Dementia
collaboration to disseminate findings nationally.
If the HOPE programme is found to be effective, we
intend to develop an implementation pack for
commissioners to support implementation. We will also
make our intervention materials freely available,
including the intervention manual, training package and
supporting documentation, if effectiveness is
demonstrated. Alongside journal publication, we will
also aim to present at conferences nationally and
internationally. Profession-specific circulations/forums
will also be utilised to disseminate results. The clinical/
research teams at trial sites will be provided with a trial
results summary. We intend to produce an output
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specifically for the trial participants and their families,
summarising the trial findings in a lay publication for
circulation. This will be supplemented with information
on our web site and social media.
Discussion
Screening processes
Feasibility discussions, setting-up and starting recruit-
ment at trial sites, demonstrate that all trial sites are dif-
ferent in terms of service provision and pathways
through the acute hospital, to intermediate care services.
The foci of screening and recruitment activity differ be-
tween organisations, but a challenge facing all research
teams is the numerous pathways from admission to ul-
timate rehabilitation discharge, and the variability and
unpredictable duration of patients’ time under the care
of those services. Screening and recruitment is challen-
ging when split across many services and settings be-
tween both hospital services and separate bed-based and
community-based rehabilitation services. Local research
teams’ screening and tracking processes for potential
participants are likely to evolve over time as services
evolve and pathways potentially change.
Intervention training
To maximise HOPE programme intervention fidelity, a
therapist training package will be delivered to all
interventional therapists. Intervention training will include
clinical reasoning for the HOPE programme exercises,
behaviour change strategies and practical delivery of the
programme. Research principles including the importance
of avoiding contamination via providing intervention
principles to control participants will also be discussed.
Supervision of therapy staff will be by usual NHS line
management. Details of training provision, including
content, attendance, duration, and training providers will
be documented. Intervention therapists will have access to
training materials to support intervention delivery.
Therapists will be provided with ongoing trial-specific
training updates via teleconferences and newsletters.
Training refresher sessions will be available for therapists
where a gap in intervention provision has occurred, or
upon request. New therapists joining the team due to ro-
tations/turnover will be provided with the same training
package. Any significant intervention training updates will
be communicated directly with all therapists individually
via email. The central trial team manager (physiotherapist)
will seek site intervention team review meetings and feed-
back in the early stages of site opening.
Potential impact of the HERO trial
This trial seeks to determine if the HOPE programme as
extended rehabilitation for older people with frailty
following acute illness or injury can improve physical
health-related quality of life. The HOPE programme will
be embedded within existing NHS services and pathways
in a wide range of trusts both in terms of geography and
size, and the diversity of the populations, to make the
trial findings generalisable to a population of older
people with frailty. The trial is powered such that robust
conclusions may be drawn around clinical and cost-
effectiveness of a theory-driven exercise intervention
with potential for improved health-related quality of life.
The results will improve awareness of the rehabilitation
needs of older people with frailty. Findings from the em-
bedded process evaluation will contribute to understand-
ing factors which would facilitate wider implementation
of the HOPE programme, these include factors influen-
cing trial implementation, intervention fidelity, and the
experiences and perspectives of trial participants and
providers. The HERO trial findings will have consider-
able potential for benefit to older people with frailty and
for health and social care services, through the commis-
sioning and delivery of evidence-based rehabilitation ser-
vices, if effectiveness is demonstrated.
Trial status
Protocol v5.0 27/01/2020. Recruitment began December
2017 and is expected to conclude August 2021.
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